Animal Pharm's Top 20: 2006 Edition

Table of Contents

CHAPTER 1 INTRODUCTION

• 1.1 The world market for animal health and nutrition products
  • 1.1.1 Market shares by region
  • 1.1.2 Market shares by product category
  • 1.1.3 Market shares by species
• 1.2 The animal health and nutrition products industry
  • 1.2.1 Leading companies in the animal health and nutrition sector
    • 1.2.1.1 Market leaders in 2005
    • 1.2.1.2 Market leaders in 2006
  • 1.2.2 Industry profit levels
• 1.3 Currencies and exchange rates used in this report

CHAPTER 2 ADISSEO

• 2.1 Company background
• 2.2 Animal nutrition sales
  • 2.2.1 2004 performance
  • 2.2.2 2005 performance
  • 2.2.3 Interim 2006 performance
• 2.3 Geography of the business
  • 2.3.1 Europe, Middle East, Africa and CIS
  • 2.3.2 Asia/Pacific
  • 2.3.3 Latin America
  • 2.3.4 North America
• 2.4 Product portfolio
  • 2.4.1 Methionine
  • 2.4.2 Vitamins
  • 2.4.3 Enzymes
• 2.5 R&D
• 2.6 Strategy
• 2.7 Prospects

CHAPTER 3 ALPHARMA

• 3.1 Company background
• 3.2 Animal health sales and operating profit
  • 3.2.1 2004 performance
  • 3.2.2 2005 performance
  • 3.2.3 Interim 2006 performance
• 3.3 Geography of the business
  • 3.3.1 US
  • 3.3.2 International markets
• 3.4 Product portfolio
  • 3.4.1 Antibiotics
  • 3.4.2 Anticoccidials
  • 3.4.3 Antibacterials
  • 3.4.4 Other products
• 3.5 R&D
• 3.6 Strategy
• 3.7 Prospects

CHAPTER 4 BASF

• 4.1 Company background
• 4.2 Animal nutrition sales
  • 4.2.1 2004 performance
  • 4.2.2 2005 performance
  • 4.2.3 Interim 2006 performance
• 4.3 Geography of the business
  • 4.3.1 Europe
  • 4.3.2 Americas
  • 4.3.3 Asia/Pacific
• 4.4 Product portfolio
  • 4.4.1 Vitamins
  • 4.4.2 Amino acids
  • 4.4.3 Carotenoids
  • 4.4.4 Enzymes
  • 4.4.5 Other products
• 4.5 R&D
• 4.6 Strategy
• 4.7 Prospects

CHAPTER 5 BAYER

• 5.1 Company background
• 5.2 Animal health sales and operating income
  • 5.2.1 2004 performance
  • 5.2.2 2005 performance
  • 5.2.3 Interim 2006 performance
• 5.3 Geography of the business
  • 5.3.1 North America
  • 5.3.2 Europe
  • 5.3.3 Asia/Pacific
  • 5.3.4 Latin America, Africa & Middle East
• 5.4 Product portfolio
  • 5.4.1 Antiparasitics
  • 5.4.2 Antimicrobials
  • 5.4.3 Other products
• 5.5 R&D
• 5.6 Strategy
• 5.7 Prospects

CHAPTER 6 BOEHRINGER INGELHEIM

• 6.1 Company background
• 6.2 Animal health sales
  • 6.2.1 2004 performance
  • 6.2.2 2005 performance
  • 6.2.3 Interim 2006 performance
• 6.3 Geography of the business
  • 6.3.1 Europe
  • 6.3.2 North America
  • 6.3.3 Other markets
• 6.4 Product portfolio
  • 6.4.1 Pharmaceuticals
  • 6.4.2 Biologicals
  • 6.4.3 Other products
• 6.5 R&D
• 6.6 Strategy
• 6.7 Prospects

CHAPTER 7 CEVA

• 7.1 Company background
• 7.2 Animal health sales and earnings
  • 7.2.1 2004 performance
  • 7.2.2 2005 performance
  • 7.2.3 Interim 2006 performance
• 7.3 Geography of the business
  • 7.3.1 Europe
  • 7.3.2 International markets
• 7.4 Product portfolio
  • 7.4.1 Companion animal and behavioral products
  • 7.4.2 Reproductive controls
  • 7.4.3 Anti-infectives
  • 7.4.4 Vaccines
  • 7.4.5 Others
• 7.5 R&D
• 7.6 Strategy
• 7.7 Prospects

CHAPTER 8 DAINIPPON SUMITOMO PHARMA

• 8.1 Company background
• 8.2 Animal health sales and operating profit
  • 8.2.1 Fiscal 2005 performance
  • 8.2.2 Fiscal 2006 performance
• 8.3 Geography of the business
• 8.4 Product portfolio
  • 8.4.1 Companion animal products
  • 8.4.2 Food animal products
• 8.5 R&D
• 8.6 Strategy
• 8.7 Prospects

CHAPTER 9 DEGUSSA

• 9.1 Company background
• 9.2 Feed additive sales
  • 9.2.1 2004 performance
  • 9.2.2 2005 performance
  • 9.2.3 Interim 2006 performance
• 9.3 Geography of the business
• 9.4 Product portfolio
  • 9.4.1 Methionine
  • 9.4.2 Other amino acids
• 9.5 R&D
• 9.6 Strategy
• 9.7 Prospects

CHAPTER 10 DSM

• 10.1 Company background
• 10.2 Animal nutrition sales
  • 10.2.1 2004 performance
  • 10.2.2 2005 performance
  • 10.2.3 Interim 2006 performance
• 10.3 Geography of the business
• 10.4 Product portfolio
  • 10.4.1 Vitamins
  • 10.4.2 Carotenoids
  • 10.4.3 Feed enzymes
  • 10.4.4 Other products
• 10.5 R&D
• 10.6 Strategy
• 10.7 Prospects

CHAPTER 11 ELANCO

• 11.1 Company background
• 11.2 Animal health sales and operating income
  • 11.2.1 2004 performance
  • 11.2.2 2005 performance
  • 11.2.3 Interim 2006 performance
• 11.3 Geography of the business
  • 11.3.1 US
  • 11.3.2 International markets
• 11.4 Product portfolio
  • 11.4.1 Tylosin
  • 11.4.2 Tilmicosin
  • 11.4.3 Monensin
  • 11.4.4 Avilamycin
  • 11.4.5 Ractopamine
  • 11.4.6 Other products
• 11.5 R&D
• 11.6 Strategy
• 11.7 Prospects

CHAPTER 12 FORT DODGE

• 12.1 Company background
• 12.2 Animal health sales and operating profit
  • 12.2.1 2004 performance
  • 12.2.2 2005 performance
  • 12.2.3 Interim 2006 performance
• 12.3 Geography of the business
  • 12.3.1 US
  • 12.3.2 International markets
• 12.4 Product portfolio
  • 12.4.1 Biologicals
  • 12.4.2 Antiparasitics
  • 12.4.3 Other pharmaceuticals
• 12.5 R&D
• 12.6 Strategy
• 12.7 Prospects

CHAPTER 13 IDEXX

• 13.1 Company background
• 13.2 Sales and income
  • 13.2.1 2004 performance
  • 13.2.2 2005 performance
  • 13.2.3 Interim 2006 performance
• 13.3 Geography of the business
  • 13.3.1 North America
  • 13.3.2 International markets
• 13.4 Product portfolio
  • 13.4.1 Companion animal group
    • 13.4.1.1 Immunoassays
    • 13.4.1.2 Veterinary instrument systems
    • 13.4.1.3 Reference laboratory and consulting services
    • 13.4.1.4 Information management and radiography
    • 13.4.1.5 Veterinary pharmaceuticals
  • 13.4.2 Water products and services
  • 13.4.3 Food diagnostics group
• 13.5 R&D
• 13.6 Strategy
• 13.7 Prospects

CHAPTER 14 INTERVET

• 14.1 Company background
• 14.2 Animal health sales and operating profit
  • 14.2.1 2004 performance
  • 14.2.2 2005 performance
  • 14.2.3 Interim 2006 performance
• 14.3 Geography of the business
  • 14.3.1 Europe
  • 14.3.2 Americas
  • 14.3.3 Other markets
• 14.4 Product portfolio
  • 14.4.1 Biologicals
  • 14.4.2 Antiparasitics
  • 14.4.3 Anti-infectives
  • 14.4.4 Other products
• 14.5 R&D
• 14.6 Strategy
• 14.7 Prospects

CHAPTER 15 MERIAL

• 15.1 Company background
• 15.2 Animal health sales
  • 15.2.1 2004 performance
  • 15.2.2 2005 performance
  • 15.2.3 Interim 2006 performance
• 15.3 Geography of the business
• 15.3.1 US
  • 15.3.2 Europe
  • 15.3.3 International
• 15.4 Product portfolio
  • 15.4.1 Avermectins
  • 15.4.2 Fipronil
  • 15.4.3 Biologicals
  • 15.4.4 Other products
• 15.5 R&D
• 15.6 Strategy
• 15.7 Prospects

CHAPTER 16 NOVARTIS

• 16.1 Company background
• 16.2 Animal health sales and operating profit
  • 16.2.1 2004 performance
  • 16.2.2 2005 performance
  • 16.2.3 Interim 2006 performance
• 16.3 Geography of the business
  • 16.3.1 North America
  • 16.3.2 Europe
  • 16.3.3 Other markets
• 16.4 Product portfolio
  • 16.4.1 Antiparasitics
  • 16.4.2 Anti-infectives
  • 16.4.3 Other pharmaceuticals
  • 16.4.4 Vaccines
• 16.5 R&D
• 16.6 Strategy
• 16.7 Prospects

CHAPTER 17 PFIZER

• 17.1 Company background
• 17.2 Animal health sales and operating profit
  • 17.2.1 2004 performance
  • 17.2.2 2005 performance
  • 17.2.3 Interim 2006 performance
• 17.3 Geography of the business
  • 17.3.1 US
  • 17.3.2 International markets
• 17.4 Product portfolio
  • 17.4.1 Anti-infectives
  • 17.4.2 Antiparasitics
  • 17.4.3 Vaccines
  • 17.4.4 Other pharmaceuticals
• 17.5 R&D
• 17.6 Strategy
• 17.7 Prospects

CHAPTER 18 PHIBRO

• 18.1 Company background
• 18.2 Animal health & nutrition sales and operating profit
  • 18.2.1 Fiscal 2004 performance
  • 18.2.2 Fiscal 2005 performance
  • 18.2.3 Interim fiscal 2006 performance
• 18.3 Geography of the business
• 18.4 Product portfolio
  • 18.4.1 Phibro Animal Health
  • 18.4.2 Koffolk
  • 18.4.3 Prince Agri Products
• 18.5 R&D
• 18.6 Strategy
• 18.7 Prospects

CHAPTER 19 SCHERING-PLOUGH

• 19.1 Company background
• 19.2 Animal health sales and earnings
  • 19.2.1 2004 performance
  • 19.2.2 2005 performance
  • 19.2.3 Interim 2006 performance
• 19.3 Geography of the business
  • 19.3.1 US
  • 19.3.2 International markets
• 19.4 Product portfolio
  • 19.4.1 Antiparasitics
  • 19.4.2 Anti-infectives
  • 19.4.3 Vaccines
  • 19.4.4 Other products
• 19.5 R&D
• 19.6 Strategy
• 19.7 Prospects

CHAPTER 20 VETOQUINOL

• 20.1 Company background
• 20.2 Animal health sales
  • 20.2.1 2004 performance
  • 20.2.2 2005 performance
  • 20.2.3 Interim 2006 performance
• 20.3 Geography of the business
  • 20.3.1 Europe
  • 20.3.2 North America
  • 20.3.3 Other markets
• 20.4 Product portfolio
  • 20.4.1 Anti-infectives
  • 20.4.2 Other pharmaceuticals
  • 20.4.3 Other products
• 20.5 R&D
• 20.6 Strategy
• 20.7 Prospects

CHAPTER 21 VIRBAC

• 21.1 Company background
• 21.2 Animal health sales and operating profit
  • 21.2.1 2004 performance
  • 21.2.2 2005 performance
  • 21.2.3 Interim 2006 performance
• 21.3 Geography of the business
  • 21.3.1 Europe
  • 21.3.2 North America
  • 21.3.3 Other markets
• 21.4 Product portfolio
  • 21.4.1 Antiparasitics
  • 21.4.2 Anti-infectives
  • 21.4.3 Biologicals
  • 21.4.4 Other products
• 21.5 R&D
• 21.6 Strategy
• 21.7 Prospects